Personalised service, backed by global depth.
Diatranz Otsuka Limited (DOL) was established in New Zealand in 2011 as a joint-venture between Living Cell Technologies and Otsuka Pharmaceutical factory, initially to focus on the development and commercialisation of DIABECELL as a treatment for Type 1 diabetes. In January 2018, DOL became a wholly owned subsidiary of Otsuka Pharmaceutical Factory, Inc. (OPF) one of the main operating companies of the Otsuka Group.
OPF continues to pursue the development of DIABECELL through clinical trials in the USA, with DOL providing quality assurance testing services to support these trials, from verification of herd safety through to diagnostic testing of human clinical samples.
Alongside its services to OPF, DOL provides advanced molecular diagnostic and analytical services to pharmaceutical, medical device and xenotransplantation customers across the globe.
Contact us
Interested in working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!